We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Monoclonaux contre TKI A pour les anti-REGF.
- Authors
Bozec, A.; Dassonville, O.; Poissonnet, G.; Peyrade, F.; Fischel, J.-L.; Milano, G.
- Abstract
The development of targeted agents in oncology is currently in rapid growth, focusing primarily on two large categories of molecules, monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs). Among these new products, those that target the epidermal growth factor receptor (EGFR) presently show the most promise in terms of therapeutic outcome. EGFR and its signaling pathways play a key role in the regulation of cell proliferation, survival and differentiation, making this receptor a major target in cancer treatment. Cetuximab (Erbitux®), amAb, gefitinib (Iressa®) and erlotinib (Tarceva®), both TKIs, are the most clinically advanced agents that target EGFR. The purpose of this article is to compare the key experimental and clinical data regarding the activity of these two types of molecules.
- Subjects
CETUXIMAB; ANTINEOPLASTIC agents; MONOCLONAL antibodies; CANCER treatment; EPIDERMAL growth factor; CELL proliferation; GROWTH factors; THERAPEUTICS
- Publication
Oncologie (Tech Science Press), 2006, Vol 8, Issue 9, p842
- ISSN
1292-3818
- Publication type
Article
- DOI
10.1007/s10269-006-0522-z